Developed under the auspices of the University of Glasgow supported by unrestricted educational grants from Pfizer Italia S.r.l. and R-Pharm CJSC
The use of cytokine inhibitors as a treatment for inflammatory diseases is at the forefront of scientific development and is beginning to move from clinical trials into practice. With the approval of tofacitinib in many countries and other agents moving into phase II/III trials, staying current with the ongoing research is critical to clinical practice. The development of these agents brings in new targeted therapy and has the potential of great benefit to patients. This course outlines recent developments in cytokine signalling and IL-6 inhibition and show how these developments may come to clinical fruition over the coming years.
By following this programme, you will be able to:
Professor Leonard Calabrese
Director & Professor of Medicine,
Leonard Calabrese is a Professor of Medicine, Vice Chair of the Cleveland Clinic’s Department of Rheumatic and Immunologic Diseases and the Co-director of the Centre for Vasculitis Care and Research. He also serves as Director of the RJ Fasenmyer Centre for Clinical Immunology at the Cleveland Clinic. He also holds appointments in the Department of Infectious Diseases and the Wellness Institute.
He is a graduate of the Kansas City University of Medicine and Biosciences. Completed his internal medicine training at the Cleveland Clinic Foundation in Ohio, followed by a fellowship in rheumatic and immunologic disease. Professor Calabrese has received numerous awards, including honorary Doctorates of Humane Letters from the Kansas City University of Medicine and Biosciences and Alma College and the Leonard Tow Humanitarianism in Medicine award from the Arnold P Goldman MD Foundation.
He has particular interest in vascular inflammatory disease of the central nervous system, primary and secondary immunodeficiency states and the intersection of infections and autoimmunity. Over the course of his academic research career, Professor Calabrese has authored over 400 publications including book chapters and peer-reviewed journal articles.
|Emerging cytokine signalling agents - where are we in 2015?||
Professor Roy Fleischmann
Clinical Professor of Medicine,
Dr. Fleischmann is a Clinical Professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center and in private practice at Rheumatology Associates, Dallas, Texas. He has served as Chief of the Division of Rheumatology at UTSMC-University Hospitals-St. Paul, Dallas, Texas since 1978. Dr. Fleishmann is Co-Medical Director of Metroplex Clinical Research Center.
He received his Doctor of Medicine (M.D.) from the State University of New York, Downstate Medical Center in 1969, before completing his residency in Internal Medicine at the Mt Sinai Hospital, New York City, New York, and his Fellowship in Rheumatology at the College of Physicians and Surgeons, Columbia University, New York City, New York.
|Tofacitinib: clinical data update||
Professor Iain B. McInnes
Muirhead Professor of Medicine, Director of the Institute of Infection, Immunity and Inflammation,
Professor Iain McInnes studied medicine at the University of Glasgow and graduated with honours in 1989 before training in internal medicine and rheumatology. He completed his membership of the Royal College of Physicians (MRCP) in 1992 and became a fellow (FRCP) in 2003. He completed his PhD and post-doctoral studies via fellowships from the Wellcome Trust, the Arthritis Research Campaign (ARC, UK) and the National Institute of Health (NIH) Fogarty Fellowship Programme in both Glasgow and Bethesda, Maryland, USA.
Professor McInnes’ research interests include understanding the role of cytokines in inflammatory synovitis. He leads a trials unit specialising in the use of biologic agents in early clinical trials in inflammatory arthritis. Professor McInnes has published widely in the areas of immunobiology and rheumatology, and he is Associate Editor of Annals of Rheumatic Diseases and a member of the executive Editorial Board of the European Journal of Immunology. His work, together with that of his colleagues at the University of Glasgow, has been widely recognised and has received many prizes and lectureships including the Michael Mason Prize 2001 from the British Society for Rheumatology, the Albrecht Hasinger Lectureship 2002, the Nana Svartz Lectureship 2008, and the Dunlop Dotteridge Lectureship for the Canadian Rheumatology Association in 2010. He gave the British Society of Rheumatology (BSR) Droitwich Lecture in 2012, and the Gerald Weissmann Lecture in Rheumatology in New York in 2013. A previous Chairman of The European League Against Rheumatism (EULAR) Scientific Committee, he is now Liaison Officer to the American College of Rheumatology for EULAR. He was elected a fellow of the Royal Society of Edinburgh in 2008, and in 2012 was elected as a Fellow of the Academy of Medical Sciences.
|The emerging safety profile of JAK inhibitors||
Professor Kevin Winthrop
Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology,
Professor Kevin Winthrop received his undergraduate degree in biology from Yale University and completed his MD degree at Oregon Health Sciences University in Portland, Oregon, USA. He obtained a masters degree in epidemiology at University California at Berkeley and completed an infectious disease epidemiology fellowship with the US Centers for Disease Control and Prevention (CDC) before serving as a staff member at CDC. He has co-authored more than 100 publications, many detailing epidemiologic and clinical aspects of infections and other adverse events associated with immune-mediated inflammatory diseases, particularly those related to biologic immunosuppressive therapies. Professor Winthrop also serves on the editorial board of Annals of Rheumatic Diseases, as Section Editor of Current Rheumatology Reports, and as an Associate Editor of BMC Infectious Diseases.
Date of preparation: December 2015